These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 23589177)

  • 21. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
    Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies.
    Xie B; Wan J; Chen X; Han W; Wang H
    Mol Cancer Ther; 2020 Mar; 19(3):822-834. PubMed ID: 31848296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of resistance to cabazitaxel.
    Duran GE; Wang YC; Francisco EB; Rose JC; Martinez FJ; Coller J; Brassard D; Vrignaud P; Sikic BI
    Mol Cancer Ther; 2015 Jan; 14(1):193-201. PubMed ID: 25416788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
    de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
    Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.
    Reynolds CP; Kang MH; Maris JM; Kolb EA; Gorlick R; Wu J; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2015 Nov; 62(11):1897-905. PubMed ID: 26154614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
    Paller CJ; Antonarakis ES
    Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics.
    Reddy LH; Bazile D
    Adv Drug Deliv Rev; 2014 May; 71():34-57. PubMed ID: 24184489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ERG induces taxane resistance in castration-resistant prostate cancer.
    Galletti G; Matov A; Beltran H; Fontugne J; Miguel Mosquera J; Cheung C; MacDonald TY; Sung M; O'Toole S; Kench JG; Suk Chae S; Kimovski D; Tagawa ST; Nanus DM; Rubin MA; Horvath LG; Giannakakou P; Rickman DS
    Nat Commun; 2014 Nov; 5():5548. PubMed ID: 25420520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
    de Leeuw R; Berman-Booty LD; Schiewer MJ; Ciment SJ; Den RB; Dicker AP; Kelly WK; Trabulsi EJ; Lallas CD; Gomella LG; Knudsen KE
    Clin Cancer Res; 2015 Feb; 21(4):795-807. PubMed ID: 25691773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
    Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
    Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
    Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
    Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
    Chao OS; Goodman OB
    Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
    Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
    Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on taxane development: new analogs and new formulations.
    Yared JA; Tkaczuk KH
    Drug Des Devel Ther; 2012; 6():371-84. PubMed ID: 23251087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cabazitaxel in metastatic castration-resistant prostate cancer.
    Yap TA; Pezaro CJ; de Bono JS
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1129-36. PubMed ID: 23098113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.
    Liu D; Liu Z; Wang L; Zhang C; Zhang N
    Colloids Surf B Biointerfaces; 2011 Jul; 85(2):262-9. PubMed ID: 21435845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
    Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cabazitaxel, a new taxane with favorable properties.
    Bouchet BP; Galmarini CM
    Drugs Today (Barc); 2010 Oct; 46(10):735-42. PubMed ID: 21076710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.